FOXO Technologies mid-year update: Q1 revenue $5.1M, loss narrowed, potential $10M+ Vector acquisition

FOXO TECHNOLOGIES INC.

Q1 2026 net revenues $5.1M vs $3.2M YoY; operating loss narrowed to $0.3M from $1.5M.
Effected 1:3,000 reverse stock split; exchanged ~$7.8M Series A Preferred into non-convertible debt to reduce dilution.
Entered agreement with former CEO Jon Sabes to license epigenetics IP for 3% royalty (cap $1.3M) and ten-year option for majority ownership.
Myrtle Recovery Centers operating at 92% occupancy; seeking expansion to 32 beds; annualized admissions ~700 in 2026.
Vector BioSource evaluating acquisition that could add >$10M annual revenue; company considering uplisting to NYSE American.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.